Authentica Global
Markets S&P 500 7,543.64 ▲ 0.81% Nasdaq 26,206.89 ▲ 1.30% Dow Jones 52,487.41 ▲ 0.27% US 10 Yr 4.54 ▼ 0.66% Crude Oil 71.87 ▼ 0.29% Gold 4,131.40 ▼ 0.23% Bitcoin 63,175 ▲ 1.51% FTSE 100 10,472.45 ▼ 0.16% EUR/USD 1.1436 ▲ 0.02% Nikkei 225 67,743.85 ▲ 1.38%
Topic archive

Vertex Pharmaceuticals

Reporting, analysis and commentary on Vertex Pharmaceuticals from Authentica Global, drawn together from across our coverage.

1 article Latest update: 5 Jul 2026 1 section
Related sections Health
Related topics Casgevy sickle cell children sickle cell disease CRISPR gene therapy FDA approval pediatric medicine gene editing
Tag lead
A young child with sickle cell disease receiving care in a hospital as clinicians prepare a gene-editing stem cell treatment
Health

FDA Approval of Casgevy Sickle Cell Children Opens a Cure to Kids as Young as 2

5,500 additional American children become newly eligible for a one-time cure after the FDA expanded Vertex's CRISPR therapy Casgevy to patients as young as 2 with sickle cell disease on July 1, 2026.

5 Jul 2026 ·9 min read
Keep reading

More paths through this story

This archive gathers Authentica Global coverage of Vertex Pharmaceuticals, bringing together the reporting, analysis and commentary connected to the subject.

Related topics

Casgevy sickle cell children sickle cell disease CRISPR gene therapy FDA approval pediatric medicine gene editing Federal Reserve Donald Trump AI infrastructure nonfarm payrolls

Related sections

Health

Latest nearby

Health · 5 Jul 2026 Colorado Enbrel Price Cap Blocked, Pharma Pockets the Win Health · 5 Jul 2026 US Measles Elimination Status 2026 Cracks at 2,170 Cases Health · 5 Jul 2026 Aetna, Cigna Headline ACA Marketplace Insurers Exit 2026 Health · 5 Jul 2026 Dead Skua Marks First H5N1 Bird Flu Australia Detection